Back to Journals » Biologics: Targets and Therapy » Volume 13

Dupilumab side effect in a patient with atopic dermatitis: a case report study

Authors Albader SS, Alharbi AA, Alenezi RF, Alsaif FM

Received 21 November 2018

Accepted for publication 20 February 2019

Published 13 May 2019 Volume 2019:13 Pages 79—82


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Doris Benbrook

Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif3

1College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Abstract: Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.

Keywords: atopic dermatitis, dupilumab, eczema, adverse effect

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]